No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly females |
293218 |
2. Check conditionsNone |
293218 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
236 |
4. Check minimum number of eventsNone |
236 |
5. Include endpointsNone |
236 |
6. Filter based on genotype QC (FinnGen only) |
225 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Squamous cell neoplasms and carcinoma of cervix
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of cervix uteri
- Malignant neoplasm of cervix uteri, including Hilmo
- malignant neoplasm of female genital organs
- Solid cancers, helper endpoint
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 225 | 225 | - |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | - |
| Median age at first event (years) | 43.13 | 43.13 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 236
- Matched controls
- 2360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8070/3-C53.9
ICD-O-3
Squamous cell carcinoma, NOS, of cervix uteri
+∞
217.9
174
*
C53.11
ICD-10 Finland
Squamous cell carcinoma and exocervix
+∞
139.9
120
*
C53.01
ICD-10 Finland
Squamous cell carcinoma of the endocervix
+∞
115.3
101
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
81.0
73
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
10.9
76.9
124
218
ULA02
NOMESCO Finland
Kolposcopy
10.9
74.9
115
190
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
17.0
74.4
70
57
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
11.8
71.3
92
121
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
9.0
58.8
98
173
A04AA01
ATC
ondansetron; systemic, rectal
17.7
51.6
45
31
JN4BD
NOMESCO Finland
Extensive body CT
14.4
48.7
48
41
H02AB02
ATC
dexamethasone; systemic
84.8
48.5
53
8
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
45.3
42
*
XX3DW
NOMESCO Finland
Time consuming IT work
12.5
43.7
47
46
WF002
NOMESCO Finland
Radical radiotherapy
169.3
41.2
42
*
LCD30
NOMESCO Finland
Radical hysterectomy
+∞
38.6
36
*
8070/3-C53.1
ICD-O-3
Squamous cell carcinoma, NOS, of exocervix
+∞
38.6
36
*
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
12.1
36.1
39
38
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
+∞
35.3
33
*
A03FA01
ATC
metoclopramide; systemic, rectal
5.5
34.4
93
250
A04AA55
ATC
palonosetron, combinations; systemic
+∞
33.1
31
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
50.0
32.0
38
9
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
+∞
30.9
29
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
122.8
30.5
32
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
29.8
28
*
LCD31
NOMESCO Finland
Radical laparoscopic hysterectomy
+∞
29.8
28
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
28.7
27
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
28.7
27
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
29.0
27.6
37
15
C53.1
ICD-10 Finland
Malignant neoplasm: Exocervix
+∞
26.6
25
*
PJA12
NOMESCO Finland
Sentinel node biopsy
290.7
26.2
26
*
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
50.7
26.2
31
7
B01AB10
ATC
tinzaparin; parenteral
6.4
25.9
49
93
ZXC96
NOMESCO Finland
Robot assisted procedure
65.7
25.6
29
5
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
25.5
24
*
C53.00
ICD-10 Finland
Malignant tumor of endocervix without histology
+∞
24.4
23
*
LDA10
NOMESCO Finland
Curettage of cervix uteri
7.0
23.8
40
67
8070/3-C53.0
ICD-O-3
Squamous cell carcinoma, NOS, of endocervix
+∞
23.3
22
*
N87.2
ICD-10 Finland
Severe cervical dysplasia, not elsewhere classified
9.8
22.9
28
32
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
22.2
21
*
A04AA02
ATC
granisetron; systemic, transdermal
241.4
22.0
22
*
LEB00
NOMESCO Finland
Biopsy of vagina
21.6
22.0
32
17
ZX120
NOMESCO Finland
Intravenous
7.2
21.7
35
56
C53.0
ICD-10 Finland
Malignant neoplasm: Endocervix
+∞
21.2
20
*
Z51.5
ICD-10 Finland
Palliative care
19.6
20.7
31
18
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
20.1
19
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
20.1
19
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
114.8
19.9
21
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
217.5
19.9
20
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
19.0
18
*
C53.10
ICD-10 Finland
Malignant tumor of the exocervix without histology
+∞
17.9
17
*
8310
FHL
Radical hysterectomy (includes lymph node removal)
+∞
16.9
16
*
A04AD12
ATC
aprepitant; systemic
+∞
16.9
16
*
18099
ICD-8 Finland
Malignant neoplasm of cervix uteri
+∞
16.9
16
*
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
16.9
16
*
C53.81
ICD-10 Finland
Overall squamous cell carcinoma of the cervix uteri
+∞
16.9
16
*
L03AA13
ATC
pegfilgrastim; parenteral
182.4
16.7
17
*
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
43.5
16.6
20
5
WZC00
NOMESCO Finland
Treatment plan or consultation
3.2
16.6
98
427
WZC30
NOMESCO Finland
Teaching
4.5
16.4
45
117
WW500
NOMESCO Finland
Blood transfusion
14.4
16.1
27
21
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
3.7
16.0
61
201
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
15.8
15
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
15.8
15
*
UKC02
NOMESCO Finland
Cystoscopy
4.3
15.4
46
127
JN4AD
NOMESCO Finland
Body CT examination
7.4
15.1
23
34
L03AA02
ATC
filgrastim; parenteral
+∞
14.7
14
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
14.7
14
*
C53
ICD-10 Finland
Malignant neoplasm of cervix uteri
+∞
14.7
14
*
N02AA05
ATC
oxycodone; systemic
3.7
14.2
54
177
B01AB05
ATC
enoxaparin; parenteral
3.0
14.1
93
424
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
2.8
13.9
122
648
C53.91
ICD-10 Finland
Squamous cell carcinoma in an unspecified location in the cervix
+∞
13.7
13
*
1800A
ICD-9 Finland
Malignant neoplasm of cervix uteri, Endocervix
+∞
13.7
13
*
1801A
ICD-9 Finland
Malignant neoplasm of cervix uteri, Exocervix
+∞
13.7
13
*
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
13.7
13
*
PJ5AQ
NOMESCO Finland
Sentinell lymphnode SPECT with low dose CT
+∞
13.7
13
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
20.5
13.1
19
10
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
12.6
12
*
JN5JS
NOMESCO Finland
Extensive PET-MRI of body metabolism
+∞
12.6
12
*
115
Kela drug reimbursment
Breast cancer
+∞
12.6
12
*
PJA01
NOMESCO Finland
Laparoscopic sentinel node excision
137.0
12.6
13
*
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
68.5
11.7
13
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
11.5
11
*
C53.90
ICD-10 Finland
Malignant tumor in unspecified localization in cervix uteri without histology
+∞
11.5
11
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
11.5
11
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
11.5
11
*
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
12.8
11.1
19
16
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.3
10.8
30
78
I89.0
ICD-10 Finland
Lymphoedema, not elsewhere classified
62.9
10.7
12
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
62.9
10.7
12
*
LAG11
NOMESCO Finland
Laparoscopic oophoropexy
+∞
10.5
10
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
10.5
10
*
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
5.3
10.0
21
43
HA1AA
NOMESCO Finland
X-ray mammography
5.2
9.5
20
41
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
104.0
9.5
10
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.4
9
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
9.4
9
*
ZXE30
NOMESCO Finland
More than five and less than seven hours
8.3
9.3
20
26
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
8.9
9.3
19
23
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
7.6
9.3
21
30
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
38.3
9.1
11
*
WX892
NOMESCO Finland
Monitored bed care
4.1
8.8
25
66
130
Kela drug reimbursment
Malignant tumour
+∞
8.4
8
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
8.4
8
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
8.4
8
*
C53.99
ICD-10 Finland
Malignant tumor in unspecified localization in cervix, unspecified histology
+∞
8.4
8
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
8.4
8
*
ZXE20
NOMESCO Finland
More than three and less than five hours
3.2
8.2
36
127
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
12.3
8.2
14
12
D06.0
ICD-10 Finland
Carcinoma in situ: Endocervix
34.6
8.1
10
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.7
8.1
19
43
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.3
7
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.3
7
*
YX9VG
NOMESCO Finland
Other MRI eamination with high intensity magnet for dose design of radiotherapy
+∞
7.3
7
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
8.3
7.2
15
19
WX402
NOMESCO Finland
General anaesthesia
2.5
7.1
49
220
WX302
NOMESCO Finland
Thoracal epidural anesthesy
9.8
6.9
13
14
N87.1
ICD-10 Finland
Moderate cervical dysplasia
6.8
6.8
16
25
K56.5
ICD-10 Finland
Intestinal adhesions [bands] with obstruction
23.3
6.7
9
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
6.3
6
*
18011, ,
ICD-8 Finland
+∞
6.3
6
*
C53.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of cervix uteri
+∞
6.3
6
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
6.3
6
*
JN5KS
NOMESCO Finland
Very extensive PET-MRI of body metabolism
+∞
6.3
6
*
YL1CD
NOMESCO Finland
Very extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
3.3
6.1
24
79
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
5.8
6.1
16
29
TPH04
NOMESCO Finland
Cathetrisation of vein
2.3
6.1
51
250
TPH07
NOMESCO Finland
Cathetrisation of artery
3.3
6.1
23
74
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
102
477
3.00
14.95
2.4
1.5
—
—
—
0
0
40
104
4.43
14.47
2.0
1.5
—
—
—
0
0
115
627
2.63
11.93
6.5
3.2
33.46
36.42
g/l
4.48
107
575
105
562
2.56
11.14
4.7
2.9
—
—
—
0
0
130
785
2.46
10.44
3.9
2.2
—
—
—
0
0
31
96
3.57
8.70
2.0
1.4
—
—
—
0
0
10
6
17.31
6.80
1.0
1.5
—
—
—
0
0
67
367
2.15
6.13
3.9
1.7
—
—
—
0
0
132
933
1.94
5.83
15.1
6.4
4.14
4.12
e9/l
0.02
124
809
47
233
2.27
5.44
4.4
2.6
5.54
3.87
e6/l
0.27
29
112
113
772
1.89
5.41
8.8
4.4
1.21
1.23
mmol/l
1.48
94
674
100
669
1.86
5.01
9.5
10.4
1.08
1.20
inr
1.05
25
195
71
430
1.93
4.80
4.3
2.8
0.64
0.49
e6/l
0.24
59
316
10
14
7.40
4.70
2.6
1.8
—
—
—
0
0
47
260
2.01
4.07
4.2
2.4
1.64
1.18
e6/l
0.28
28
140
126
949
1.70
3.93
5.3
3.5
6.61
6.50
mmol/l
0.28
120
857
83
558
1.75
3.90
4.8
1.9
2.34
2.36
mmol/l
0.41
77
483
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
28
4.46
3.87
1.8
2.8
0.38
0.38
u/ml
—
6
23
31
152
2.20
3.66
11.2
3.9
1.01
1.03
mmol/l
0.12
31
133
30
146
2.21
3.61
3.7
3.0
—
—
—
0
0
151
1210
1.69
3.60
7.1
4.5
5041.43
3434.28
e6/l
—
7
18
80
552
1.68
3.34
3.7
2.5
32.80
28.80
u/l
0.31
75
525
118
901
1.62
3.29
6.3
4.9
0.00
0.00
estimate
-0.00
15
153
13
39
3.47
3.28
1.8
1.1
—
—
—
0
0
15
55
2.84
3.22
7.5
3.0
24.53
24.50
mmol/l
0.01
15
55
13
40
3.38
3.19
2.1
1.7
4.81
1.24
ug/l
0.65
13
35
118
908
1.60
3.14
4.4
3.5
0.00
0.02
estimate
0.50
15
154
158
1812
0.61
2.99
3.7
4.0
1.52
1.58
mmol/l
1.18
153
1690
5
5
10.18
2.99
1.8
1.0
—
—
—
0
0
5
5
10.18
2.99
1.8
1.0
—
—
—
0
0
17
70
2.54
2.95
1.7
1.6
—
—
—
0
0
18
78
2.42
2.82
4.7
2.8
0.22
0.21
e6/l
0.02
18
70
6
10
6.12
2.71
1.2
1.9
13.83
104.24
u/ml
—
6
10
165
1857
0.63
2.59
4.0
4.4
2.88
2.86
mmol/l
0.11
156
1729
153
1736
0.66
2.29
3.4
3.6
1.37
1.21
mmol/l
1.94
147
1604
23
122
1.98
2.25
8.1
5.4
5.16
5.22
kpa
0.09
23
117
23
122
1.98
2.25
8.1
5.4
10.43
11.55
kpa
0.65
23
117
7
19
3.76
2.16
1.1
1.1
—
—
—
0
0
10
37
2.78
2.09
3.1
4.2
44.20
16.00
mg/l
—
5
25
13
58
2.31
1.94
2.4
1.6
—
—
—
0
0
32
199
1.70
1.93
2.3
1.7
28.40
29.44
s
0.82
32
194
189
1708
1.54
1.87
21.1
9.0
80.28
83.71
ml/min/173m2
1.17
163
1346
16
80
2.07
1.85
2.1
1.6
—
—
—
0
0
9
35
2.63
1.82
1.6
1.1
—
—
—
0
0
12
54
2.29
1.77
1.9
1.6
—
—
—
0
0
8
31
2.63
1.67
2.0
3.7
22.71
24.17
mmol/l
—
8
31
13
63
2.13
1.63
3.8
3.3
47.27
43.04
%
0.20
13
63
34
492
0.64
1.63
2.1
1.6
1.74
1.36
mmol/l
1.51
26
429
6
20
3.05
1.59
1.0
1.6
—
—
—
0
0
9
183
0.47
1.59
1.3
1.7
381.67
370.02
nmol/l
—
9
169
54
403
1.44
1.49
1.5
1.7
1.44
0.93
mg/l
0.61
44
303
33
223
1.56
1.46
2.0
1.7
—
—
—
0
0
166
1808
0.72
1.42
4.5
4.1
5.95
5.76
mmol/l
1.02
156
1660
107
904
1.34
1.39
4.7
3.5
0.00
0.00
estimate
-0.00
16
169
198
1849
1.44
1.25
23.0
10.4
28.61
18.35
mg/l
3.60
172
1368
17
101
1.74
1.23
2.5
2.1
194.58
4680.51
u/l
—
10
41
8
155
0.50
1.18
1.4
1.5
—
—
—
0
0
18
113
1.64
1.09
3.5
1.6
67.30
67.24
g/l
0.01
18
106
59
476
1.32
1.02
4.4
3.7
0.00
0.00
estimate
-0.00
15
153
7
36
1.97
0.98
1.1
1.8
—
—
—
0
0
9
50
1.83
0.98
1.4
1.3
—
—
—
0
0
84
716
1.27
0.95
5.0
3.5
—
—
—
0
0
30
220
1.42
0.93
6.1
5.4
—
—
—
0
0
12
73
1.68
0.83
1.6
2.2
—
—
—
0
0
6
32
1.90
0.82
1.7
2.1
—
—
—
0
0
6
32
1.90
0.82
1.0
1.0
—
—
—
0
0
6
32
1.90
0.82
1.2
2.3
—
—
—
0
0
30
390
0.74
0.81
1.4
1.3
19.53
9.39
u/ml
0.35
12
149
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
26
0.00
0.79
0.0
1.2
—
—
—
0
0
0
26
0.00
0.79
0.0
1.2
—
—
—
0
0
170
1799
0.80
0.76
4.7
5.1
1.79
2.49
mu/l
0.54
159
1679
5
24
2.11
0.75
1.6
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
1.1
—
—
—
0
0
5
24
2.11
0.75
1.6
1.1
—
—
—
0
0
5
24
2.11
0.75
1.6
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
1.1
—
—
—
0
0
12
76
1.61
0.73
1.4
1.1
—
—
—
0
0
12
76
1.61
0.73
1.4
1.1
—
—
—
0
0
52
432
1.26
0.72
2.8
2.1
3.53
2.98
mg/l
0.62
43
368
21
152
1.42
0.72
1.8
1.7
—
—
—
0
0
21
153
1.41
0.70
1.8
1.7
—
—
—
0
0
12
78
1.57
0.67
8.0
3.4
5.05
5.30
kpa
0.47
12
73
5
28
1.80
0.66
1.8
2.4
101.00
105.18
mmol/l
—
5
28
10
62
1.64
0.66
1.6
2.3
0.65
0.65
%
—
10
62
16
112
1.46
0.65
4.1
2.3
1.24
1.23
mmol/l
0.36
16
95
102
923
1.19
0.61
3.1
2.9
168.42
66.95
ug/l
2.05
96
860
8
51
1.59
0.61
2.1
1.5
—
—
—
0
0
7
112
0.61
0.59
1.0
1.0
—
—
—
0
0
10
64
1.59
0.59
1.6
2.3
1.76
1.03
%
—
10
64
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
17
124
1.40
0.57
2.1
1.9
62.00
73.30
ml/min/173m2
—
8
50
71
626
1.19
0.57
3.0
3.3
29.05
26.26
ng/l
0.16
41
380
200
1928
1.24
0.55
26.6
11.2
74.79
68.69
umol/l
1.35
200
1928
9
60
1.52
0.55
2.3
1.8
—
—
—
0
0
10
67
1.51
0.50
9.3
4.6
24.91
25.03
mmol/l
—
10
67
32
384
0.81
0.49
1.4
1.3
13.01
38.08
iu/ml
—
10
127
7
51
1.38
0.44
1.7
1.8
—
232.00
—
0
5
0
15
0.00
0.41
0.0
1.0
—
1.07
—
0
7
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
124
1314
0.88
0.41
3.1
3.4
—
—
—
0
0
8
61
1.32
0.40
1.1
1.3
240.38
57.42
pmol/l
—
8
61
36
416
0.84
0.39
1.3
1.6
—
—
—
0
0
46
405
1.17
0.38
2.7
2.1
317.11
4178.01
umol/l
1.55
38
355
9
69
1.32
0.37
2.9
2.3
41.33
40.00
u/l
—
9
63
148
1546
0.89
0.37
4.1
4.4
14.79
14.51
pmol/l
0.78
139
1434
36
313
1.18
0.35
3.2
3.5
575.92
308.55
ng/l
0.24
26
215
16
129
1.26
0.31
1.3
1.3
—
—
—
0
0
10
76
1.33
0.28
1.3
1.8
—
—
—
0
0
42
466
0.88
0.28
1.5
1.3
0.51
3.09
u/ml
1.51
14
141
10
126
0.78
0.25
1.6
1.4
—
—
—
0
0
36
399
0.88
0.24
1.7
1.5
16.24
22.15
nmol/l
2.52
31
345
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
34
310
1.11
0.18
1.6
1.7
922.63
1177.72
nmol/l
1.05
27
229
25
277
0.89
0.17
1.8
1.9
—
—
—
0
0
123
1192
1.07
0.16
3.4
2.7
54.52
37.06
u/l
0.98
117
1119
10
116
0.86
0.12
1.9
1.4
—
—
—
0
0
204
2061
0.92
0.11
33.2
15.6
37.40
39.58
%
4.72
196
1932
134
1368
0.95
0.11
4.0
4.0
16.69
10.91
mm/h
2.60
123
1261
7
67
1.05
0.08
1.0
1.7
—
—
—
0
0
16
170
0.94
0.04
1.6
1.5
—
—
—
0
0
12
114
1.06
0.01
10.2
2.6
107.33
74.13
ng/l
0.45
12
98
24
246
0.97
0.00
1.8
1.8
—
—
—
0
0
21
209
1.01
0.00
1.3
1.6
—
—
—
0
0
70
702
1.00
0.00
2.0
1.9
84.08
97.81
pmol/l
1.72
48
347
49
485
1.01
0.00
3.9
3.4
33.66
6.44
mg/mmol
0.83
34
287
0
6
0.00
-0.00
0.0
1.3
—
247.57
—
0
6
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
75.60
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
24.25
—
0
6
0
6
0.00
-0.00
0.0
6.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
409.80
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
104.33
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
216.83
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_CERVIX_SQUAM – Squamous cell neoplasms and carcinoma of cervix
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).